Pattern of DAP12 Expression in Leukocytes from Both Healthy and Systemic Lupus Erythematosus Patients

DAP12 is an ITAM-bearing transmembrane adaptor originally identified on the surface of Natural Killer cells. A broad expression among other immune cells was later found in myeloid and lymphoid cells. However, data on DAP12 expression pattern rely only on immunoblot and microarray analysis. Here, we describe the generation and the characterization of an anti-DAP12 monoclonal antibody. Using this novel reagent, we show that DAP12 expression is restricted to innate immune cells in basal condition. Since a decreased expression of DAP12 has been suggested in NK cells of systemic lupus erythematosus patients, we have further investigated the NK cell receptor repertoire and leukocyte expression of DAP12 in these patients and no major changes were detectable when compared to controls.

[1]  I. Gunnarsson,et al.  Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus , 2009, Immunology.

[2]  D. Gladman,et al.  KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. , 2007, Tissue Antigens.

[3]  C. Biron,et al.  DAP12 signaling regulates plasmacytoid dendritic cell homeostasis and down-modulates their function during viral infection. , 2006, The Journal of Immunology.

[4]  L. Lanier,et al.  Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121 , 2006, The Journal of Immunology.

[5]  P. Anderson,et al.  Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number. , 2006, The Journal of laboratory and clinical medicine.

[6]  D. Isenberg,et al.  Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients , 2005, Clinical and experimental immunology.

[7]  L. Lanier,et al.  Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12 , 2005, Nature Immunology.

[8]  Eric Vivier,et al.  KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions , 2005, European journal of immunology.

[9]  S. Toyabe,et al.  Decreased DAP12 expression in natural killer lymphocytes from patients with systemic lupus erythematosus is associated with increased transcript mutations. , 2004, Journal of autoimmunity.

[10]  J. Moreau,et al.  Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions , 2004, European journal of immunology.

[11]  P. Leibson,et al.  Stimulatory Killer Ig-Like Receptors Modulate T Cell Activation through DAP12-Dependent and DAP12-Independent Mechanisms1 , 2004, The Journal of Immunology.

[12]  É. Vivier,et al.  Contrasting roles of DAP10 and KARAP/DAP12 signaling adaptors in activation of the RBL‐2H3 leukemic mast cell line , 2003, European journal of immunology.

[13]  C. Buonsanti,et al.  Impaired Differentiation of Osteoclasts in TREM-2–deficient Individuals , 2003, The Journal of experimental medicine.

[14]  L. Peltonen,et al.  DAP12/TREM2 Deficiency Results in Impaired Osteoclast Differentiation and Osteoporotic Features , 2003, The Journal of experimental medicine.

[15]  N. Copeland,et al.  Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. , 2003, Biochemical and biophysical research communications.

[16]  D. Tenen,et al.  Paired Activating and Inhibitory Immunoglobulin-like Receptors, MAIR-I and MAIR-II, Regulate Mast Cell and Macrophage Activation , 2003, The Journal of experimental medicine.

[17]  É. Vivier,et al.  Selective Activation of the c-Jun NH2-terminal Protein Kinase Signaling Pathway by Stimulatory KIR in the Absence of KARAP/DAP12 in CD4+ T Cells , 2003, The Journal of experimental medicine.

[18]  K. Tan-Takeuchi,et al.  Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. , 2003, The Journal of clinical investigation.

[19]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[20]  A. Orth,et al.  Large-scale analysis of the human and mouse transcriptomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Lanier,et al.  The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. , 2000, Immunology today.

[22]  Leena Peltonen,et al.  Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts , 2000, Nature Genetics.

[23]  D. Gautheret,et al.  Gene Structure, Expression Pattern, and Biological Activity of Mouse Killer Cell Activating Receptor-associated Protein (KARAP)/DAP-12* , 1998, The Journal of Biological Chemistry.

[24]  Jun Wu,et al.  Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells , 1998, Nature.

[25]  O. Cochet,et al.  A New Set of Monoclonal Antibodies Against Human FcγRII (CD32) and FcγRIII (CD16): Characterization and Use in Various Assays , 1997 .

[26]  É. Vivier,et al.  Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. , 1997, Journal of immunology.

[27]  D. Isenberg,et al.  Lymphocyte Subsets in a Large Cohort of Patients with Systemic Lupus Erythematosus , 1993, Lupus.

[28]  E. Schned,et al.  Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.

[29]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[30]  C. Confavreux,et al.  Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. , 2005, The American journal of pathology.

[31]  O. Cochet,et al.  A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. , 1997, Hybridoma.

[32]  K. Koike,et al.  A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. , 1996, The Journal of rheumatology.